🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the register
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab
2026-525685-22-00Bullous pemphigoid
Region Midtjylland, Region Sjaelland
Immune System Diseases
Denmark
31/08/2026
Phase II
Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study
2026-525465-42-00Type 2 diabetes (T2D)
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Spain, Hungary, Romania, Slovakia, Poland, Germany
31/08/2026
Phase IV
A prospective, randomized, double-blinded, placebo-controlled, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion
2026-526837-24-00Mild autonomous cortisol secretion
Medical University Of Vienna
Hormonal diseases
Austria
29/08/2026
Phase II
Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI
2025-524874-41-00Paediatric sarcoma
Rigshospitalet
Diagnosis
Denmark
28/08/2026
Phase I
An Open-Label Study of IDE034 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
2026-526299-21-00Locally Advanced/Metastatic Solid Tumors -non-small cell l…
Ideaya Biosciences Inc.
Male Urogenital Diseases
Spain
28/08/2026
Phase IV
A prospective, exploratory, parallel-group, low-intervention, phase IV, randomized, double-blind, placebo-controlled, multi-center, national, 2-arm trial to investigate efficacy and safety of Amara-Tropfen (Amara drops) in patients with irritable bowel syndrome (IBS)
2026-526668-19-00Irritable Bowel Syndrome
Weleda AG
Digestive System Diseases
Germany
28/08/2026
Phase I/II
A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies
2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…
Institut De Recherches Internationales Servier IRIS
Neoplasms
Netherlands, Spain, Germany, Italy, France, Finland
27/08/2026
Phase IV
S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial
2026-525588-41-00traumatic brain injury, subarachnoid haemorrhage, intracere…
Region Hovedstaden
Pathological Conditions, Signs and Symptoms
Denmark
27/08/2026
Phase I
Relative oral bioavailability and tolerability of hydrocortisone from 2-dimensionally printed orodispersible films in children and adolescents with primary adrenal insufficiency (REPLACE trial)
2026-526416-37-00adrenal insufficiency
Universitaetsklinikum Heidelberg AöR
Nutritional and Metabolic Diseases
Germany
27/08/2026
Phase III
A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease
2026-525207-27-00Fabry disease
Idorsia Pharmaceuticals Ltd.
Nutritional and Metabolic Diseases
Germany, France
27/08/2026
Phase II
MDMA-assisted therapy for adolescents with treatment-resistant PTSD
2024-515184-65-01Post-traumatic stress disorder
Stichting Amsterdam UMC
Mental Disorders
Netherlands
26/08/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis
2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…
Pfizer Inc.
Neoplasms
Spain, France, Italy, Ireland, Germany, Poland
26/08/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
2025-524130-26-00Gastrointestinal Cancers
Genmab A/S
Neoplasms
Italy, Belgium, France, Spain, Denmark, Netherlands, Germany
26/08/2026
Phase II
Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly
2025-524253-14-00Acromegaly
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
Hormonal diseases
Spain
26/08/2026
Phase II
A Phase 2a, proof-of-concept, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy and safety of ACT-777991 in adults with non-segmental vitiligo
2025-524865-25-00Non-segmental vitiligo
Idorsia Pharmaceuticals Ltd.
Skin and Connective Tissue Diseases
Czechia, Poland
26/08/2026
Phase I
Bioequivalence clinical trial of two formulations of empagliflozin/metformin
2026-527325-35-00Healthy volunteers
Laboratorios Normon S.A.
Not possible to specify
Spain
26/08/2026
Phase II
DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty
2026-525351-81-00chronic thromboembolic pulmonary hypertension
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
25/08/2026
Phase II
A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)
2026-525646-29-00Renal Transplantation
Nefro Avillion Clinical Development LLC
Immune system processes
Czechia, Spain, Portugal, Austria
25/08/2026
Phase III
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00Acute ischemic stroke
Fondation A De Rothschild
Nervous System Diseases
France
25/08/2026
Phase II
[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL
2025-524897-40-00invasive lobular carcinomas of the breast
Hospices Civils De Lyon
Diagnosis
France
25/08/2026
Phase I
A single and multiple ascending dose study of DFL23693 in healthy volunteers
2026-527078-35-00Osteoarthritis
Dompe' Farmaceutici S.p.A.
Musculoskeletal Diseases
France
25/08/2026
Phase I
A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
2025-523968-20-00Patients with Recurring Ovarian Cancer and Other Advanced S…
Context Therapeutics Inc.
Neoplasms
France, Spain
25/08/2026
Phase III
A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis
2025-524757-14-00Ocular Myasthenia Gravis
UCB Biopharma
Immune System Diseases
Hungary, France, Greece, Poland, Spain, Italy, Germany
25/08/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension
2025-523821-17-00narcolepsy
Harmony Biosciences Management Inc.
Nervous System Diseases
Belgium, Italy, Germany, France, Spain, Poland
25/08/2026
Rows per page Showing 126–150 of 2500
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.